| Literature DB >> 33475867 |
Dana M Harris1, Fernando F Stancampiano2, M Caroline Burton3, Ann M Moyer4, Michael J Schuh5, Jose R Valery2, Yan Bi6.
Abstract
Prescribing the right medication, at the right dose, to the right patient is the goal of every physician. Pharmacogenomic information is an emerging tool that can be used to deliver precision medicine. In this review, we discuss the pharmacogenomics of available PPIs, racial differences of CYP2C19 and how PPI pharmacogenomics affects the treatment of common gastrointestinal diseases. We also provide practical guidance on when to order pharmacogenomic testing, which test to order, and how to modify treatment based on published guidelines.Entities:
Keywords: Gastroesophageal reflux disease; Helicobacter pylori; Pharmacogenomics; Proton pump inhibitors
Mesh:
Substances:
Year: 2021 PMID: 33475867 DOI: 10.1007/s10620-020-06814-1
Source DB: PubMed Journal: Dig Dis Sci ISSN: 0163-2116 Impact factor: 3.199